Research progress in molecular pathology markers in medulloblastoma
Open Access
- 28 February 2023
- journal article
- review article
- Published by Open Exploration Publishing in Exploration of Targeted Anti-tumor Therapy
- Vol. 4 (1) , 139-156
Abstract
Medulloblastoma (MB) is the commonest primary malignant brain cancer. The current treatment of MB is usually surgical resection combined with radiotherapy or chemotherapy. Although great progress has been made in the clinical management of MB, tumor metastasis and recurrence are still the main cause of death. Therefore, definitive and timely diagnosis is of great importance for improving therapeutic effects on MB. In 2016, the World Health Organization (WHO) divided MB into four subtypes: wingless-type mouse mammary tumor virus integration site (WNT), sonic hedgehog (SHH), non-WNT/non-SHH group 3, and group 4. Each subtype of MB has a unique profile in copy number variation, DNA alteration, gene transcription, or post-transcriptional/translational modification, all of which are associated with different biological manifestations, clinical features, and prognosis. This article reviewed the research progress of different molecular pathology markers in MB and summarized some targeted drugs against these molecular markers, hoping to stimulate the clinical application of these molecular markers in the classification, diagnosis, and treatment of MB.Keywords
This publication has 130 references indexed in Scilit:
- TERT promoter mutations are highly recurrent in SHH subgroup medulloblastomaActa Neuropathologica, 2013
- Expression of the RNA Helicase DDX3 and the Hypoxia Response in Breast CancerPLOS ONE, 2013
- Novel mutations target distinct subgroups of medulloblastomaNature, 2012
- The Crosstalk of mTOR/S6K1 and Hedgehog PathwaysCancer Cell, 2012
- Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomasActa Neuropathologica, 2012
- Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 MutationsCell, 2012
- Molecular subgroups of medulloblastoma: the current consensusActa Neuropathologica, 2011
- Interleukin‐8 is associated with proliferation, migration, angiogenesis and chemosensitivityin vitroandin vivoin colon cancer cell line modelsInternational Journal of Cancer, 2011
- Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroupsActa Neuropathologica, 2011
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007